Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition.
|
press release announcing its results for the first quarter ended
March 31, 2017. A copy of the press release is attached hereto as
Exhibit 99.1 and incorporated by reference herein.
Exhibit 99.1 attached hereto, shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section. It may only be incorporated by
reference in another filing under the Exchange Act or the
Securities Act of 1933, as amended, if such subsequent filing
specifically references the information furnished to Item 2.02 of
this report.
|
Item 7.01
|
Regulation FD Disclosure.
|
materials on its website located at www.impaxlabs.com. The
presentation materials are attached hereto as Exhibit 99.2 and
incorporated herein by reference.
Exhibit 99.2 attached hereto, shall not be deemed filed for the
purposes of Section 18 of the Exchange Act, or otherwise subject
to the liabilities of that section. It may only be incorporated
by reference in another filing under the Exchange Act or the
Securities Act of 1933, as amended, if such subsequent filing
specifically references the information furnished to Item 7.01 of
this report.
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Press release issued May 10, 2017.
|
|
99.2
|
Presentation dated May 10, 2017.
|
About Impax Laboratories, Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. Impax Laboratories, Inc. (NASDAQ:IPXL) Recent Trading Information
Impax Laboratories, Inc. (NASDAQ:IPXL) closed its last trading session up +0.75 at 14.20 with 3,261,440 shares trading hands.
